Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $226.5 million.

  • Arrowhead Pharmaceuticals' Cash & Equivalents rose 120.62% to $226.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $226.5 million, marking a year-over-year increase of 120.62%. This contributed to the annual value of $226.5 million for FY2025, which is 120.62% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Cash & Equivalents of $226.5 million as of FY2025, which was up 120.62% from $102.7 million recorded in FY2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Cash & Equivalents peaked at $226.5 million during FY2025, and registered a low of $102.7 million during FY2024.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Cash & Equivalents value was $110.9 million (recorded in 2023), while the average stood at $146.7 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Cash & Equivalents tumbled by 41.44% in 2022 and then spiked by 120.62% in 2025.
  • Yearly analysis of 5 years shows Arrowhead Pharmaceuticals' Cash & Equivalents stood at $184.4 million in 2021, then crashed by 41.44% to $108.0 million in 2022, then climbed by 2.67% to $110.9 million in 2023, then dropped by 7.40% to $102.7 million in 2024, then skyrocketed by 120.62% to $226.5 million in 2025.